UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)*

Fate Therapeutics Inc.					
(Name of Issuer)					
Common stock					
(Title of Class of Securities)					
31189P102					
(CUSIP Number)					
August 31, 2021					
(Date of Event Which Requires Filing of this Statement)					
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:					
☑ Rule 13d-1(b)☐ Rule 13d-1(c)☐ Rule 13d-1(d)					
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.					

of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act

CUSIP No. 31189P102			13G	Page 2 of 5 Pages				
	T							
1	NAMES OF	NAMES OF REPORTING PERSONS						
1.	ARK Invest							
	CHECK TH	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
2.		(a) 🗆						
		(b) 🗆						
2	SEC USE O							
3.								
CITIZENSHIP OR PLACE OF ORGANIZATION								
4.	Delaware, U	nitor	l States					
	Delaware, C	inte	1 States					
		_	SOLE VOTING P	OWER				
		5.	10,786,879					
NITIN	MDED OF		SHARED VOTING	2 DOWED				
	IBER OF HARES	6.						
	FICIALLY	IALLY	0					
	NED BY EACH		SOLE DISPOSITI	VE POWER				
REP	ORTING	7.	10,790,423					
PERS	SON WITH							
		_	SHARED DISPOS	ITIVE POWER				
		8.	0					
	AGGREGA'	TE A	MOUNT BENEFIC	IALLY OWNED BY EACH REPORTING PER	SON			
9.								
	10,790,423							
	CHECK IF	ARES						
10.								
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)							
11.	11.34%							
TYPE OF REPORTING PERSON								
12.	IA							

CUSIP No. 31189P102	13G	Page 3 of 5 Pages
Item 1(a) Name of issuer:		
Fate Therapeutics Inc.		
Item 1(b) Address of issuer's principal executive of	fices:	
3535 General Atomics Court Suite 200 San Diego, CA 92121		
Item 2(a) Name of person filing:		
ARK Investment Management LLC		
Item 2(b) Address or principal business office or, if	none, residence:	
ARK Investment Management LLC 3 East 28th Street, 7th Floor New York, NY 10016		
Item 2(c) Citizenship:		
Delaware, United States		
Item 2(d) Title of class of securities:		
Common stock		
Item 2(e) CUSIP No.:		
31189P102		
Item 3. If this statement is filed pursuant to §§ 240.	.13d-1(b) or 240.13d-2(b) or (c), check whether t	the person filing is a:
(a) \square Broker or dealer registered under section 15 of t	he Act (15 U.S.C. 780);	
(b) \square Bank as defined in section 3(a)(6) of the Act (1	5 U.S.C. 78c);	
(c) \square Insurance company as defined in section 3(a)(19)	e) of the Act (15 U.S.C. 78c);	
(d) \square Investment company registered under section 8	of the Investment Company Act of 1940 (15 U.S.C	C 80a-8);
(e) ☑ An investment adviser in accordance with § 240	0.13d-1(b)(1)(ii)(E);	
(f) \square An employee benefit plan or endowment fund in	accordance with § 240.13d-1(b)(1)(ii)(F);	
(g) \square A parent holding company or control person in	accordance with § 240.13d-1(b)(1)(ii)(G);	
(h) \square A savings associations as defined in Section 3(b	o) of the Federal Deposit Insurance Act (12 U.S.C.	1813);
(i) \square A church plan that is excluded from the definition U.S.C. 80a-3);	on of an investment company under section 3(c)(14	e) of the Investment Company Act of 1940 (15
(j) \square A non-U.S. institution in accordance with § 240	.13d-1(b)(1)(ii)(J);	
(k) \square Group, in accordance with § 240.13d-1(b)(1)(ii) type of institution:	(K). If filing as a non-U.S. institution in accordance	the with § 240.13d-1(b)(1)(ii)(J), please specify the

CUS	IP No. 31189P102	13G	Page 4 of 5 Pages		
Item 4	1. Ownership				
(a)	Amount beneficially owned:				
	10,790,423				
(b)	Percent of class:				
	11.34%				
(c)	Number of shares as to which such person h	as:			
	(i) Sole power to vote or to direct the vote:	10,786,879			
(ii) Shared power to vote or to direct the vote: 0					
	(iii) Sole power to dispose or to direct the di	sposition of: 10,790,423			
	(iv) Shared power to dispose or to direct the	disposition of: 0			
Item 5	5. Ownership of 5 Percent or Less of a Class.				
Not ap	oplicable.				
Item 6	6. Ownership of More than 5 Percent on Beh	alf of Another Person.			
Not ap	pplicable.				
	7. Identification and Classification of the Sub ol Person.	osidiary Which Acquired the Security Being Rep	orted on by the Parent Holding Company or		
Not ap	oplicable.				
Item 8	3. Identification and Classification of Membe	ers of the Group.			
Not ap	oplicable.				
Item 9). Notice of Dissolution of Group.				
Not ap	oplicable.				

CUSIP No. 31189P102	13G	Page 5 of 5 Pages
---------------------	-----	-------------------

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The reporting persons agree that this statement is filed on behalf of each of them.

Dated: September 10, 2021

ARK Investment Management LLC

By: /s/ Kellen Carter

Name: Kellen Carter

Title: Chief Compliance Officer